7:50 am Morning Refreshments & Check In
UTILIZING PERSONALISED MEDICINE & PATIENT CENTRIC APPROCAHES TO DEVELOP NOVEL REGULATORY DECISION-ENABLING ENDPOINTS ACROSS VARIOUS RETINAL DISEASES
8:50 am Chair’s Opening Remarks
9:00 am Imaging the Ellipsoid Zone as a Biomarker for Clinical Trials for Inherited Retinal Diseases
Synopsis
- Ellipsoid zone as a tool to monitor disease progression and patient selection in clinical trials
- Reviewing OCT biomarkers and adaptive optics and their applications to clinical trials
- Sharing Phase 1/2 clinical trial data
9:30 am Implementing Functional Retinal Testing in Geographic Atrophy Clinical Trials
Synopsis
- Understanding the structure-function relationship in Geographic Atrophy to develop new imaging endpoints for use in clinical trials
- Utilizing different testing strategies with Microperimetry to study the response to therapies currently being developed for dry AMD
- Reviewing Microperimetry data from clinical trials in Geographic Atrophy
10:00 am Speed Networking
Synopsis
An optimal chance to network one-to-one with leading retinal imaging experts working across various retinal indications. Learn how your peers are developing novel imaging technology to reduce timelines, optimize patient detection and selection, and discuss the future of retinal imaging.
10:45 am Morning Refreshments Break
DEVELOPING SENSITIVE & SPECIFIC NOVEL RETINAL IMAGING DEVICES TO MONITOR REAL-TIME ANALYSIS & DISEASE PROGRESSION
11:00 am Developing Sensitive & Specific Novel Retinal Imaging Devices to Image Disease Progression in Clinical Trials
Synopsis
- Developing new imaging tools with high resolution and high contrast images with minimal scatter in the field of view
- Understand the possibility of live imaging in the retina to monitor diseases progression in real time and measure drug efficacy
- Early detection and diagnosis of patients via imaging
11:30 am Concepts of Microperimetry and Future Trends
Synopsis
- Principles of Microperimetry
- New trends in Microperimetry
- Future Developments
11:40 am Exploring the Use of Serial Coronary CT Imaging to Detect Atherosclerosis Progression: Lessons From the High-Risk Coronary Plaque
Synopsis
- Demonstrate how coronary CT imaging provides a reliable biomarker to detect lipid rich necrotic core (akin to geographic atrophy in the eye)
- Understand how serial image tracking reduces future heart attack risk (akin to major vision loss in GA)
- Showcase how current efforts in cardiovascular drug development have provided accepted paths to obtain FDA approval for emerging therapies (akin to EZ imaging in the eye)
12:10 pm Lunch & Networking Break
ASSESSING & NAVIGATING THE TRANSLATABILITY OF DATA WHEN USING CLINICAL IMAGING DEVICES IN PRECLINICAL MODELS
1:10 pm Leveraging Ex Vivo Retinal Imaging Technology to Establish Functional Drug Efficacy Endpoints
Synopsis
- Developing novel preclinical tools for accelerating drug discovery
- Optophysiology vs Electrophysiology: Reviewing unique ways of imaging the retina at a cellular resolution
- Functional classification or retinal ganglion cells as a measure of glaucoma model progression
1:40 pm Multimodal Imaging Methods to Assess Ocular Distribution of Suprachoroidally Administered Therapeutics for Chorioretinal Diseases
Synopsis
- Discussing various imaging techniques, such as OCT-A, SLO, colour fundus photography and retinal flatmount, their applications, limitations, and future potentials
- Assessing posterior, circumferential, and macular spread of injectate using multimodal imaging
- Evaluating translatability of preclinical ex vivo and in vivo assessment to clinics
2:10 pm In Vivo Quantification of Retinal Vascular Leakage in Diabetic Retinopathy & Wet AMD Mouse Models
Synopsis
- Understanding the requirements from in vivo models with induced retinal vascular leakage to better show drug efficacy in the preclinical stage for improved translatability in humans
- Improving models for geographic atrophy for earlier disease detection and treatment intervention
- Developing disease-specific preclinical models of macular degeneration, with human phenotypes, to achieve desired outcomes for easier translation into humans
- Exploring adaptive optics technology for in vivo examination of the individual photoreceptors and retinal vasculature to better understand retinal pathologies
2:40 pm Afternoon Networking Break
COMPARE & CONTRAST RETINAL IMAGING TOOLS FOR VARIOUS RETINAL DISORDERS INCLUDING WET AMD, DIABETIC EYE DISEASES, DRY AMD, GEOGRAPHIC ATROPHY, INHERITED RETINAL DISEASES & GLAUCOMA
3:10 pm Roundtable Discussion
Synopsis
- Understanding the Relationship between the various retinal imaging biomarkers with disease progression
- Challenges associated with the interpretation of imaging data – do they demonstrate drug safety and efficacy?
- How can AI be used to further refine knowledge from retinal imaging? Discussing the role of AI in drug target identification, safety and efficacy assessment
Moderator Feedback & Audience Debate:
Moderators will be assigned to each roundtable to facilitate discussion and collate the findings. Following the roundtable discussions, they will present back to the entire delegation and open up wider audience debate.